Genital Diseases, Female  >>  brivanib alaninate (BMS-582664)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
brivanib alaninate (BMS-582664) / ZAI Lab
NCT00888173: Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Checkmark In recurrent/persistent endometrial cancer
Jul 2014 - Jul 2014: In recurrent/persistent endometrial cancer
Completed
2
45
US
Brivanib Alaninate, Laboratory Biomarker Analysis
Gynecologic Oncology Group, National Cancer Institute (NCI)
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma
07/16
07/16

Download Options